The Global Specialty Pharmaceutical Market is projected to grow from USD 68.3 billion in 2023 to USD 1,532.8 billion by 2033, with a CAGR of 36.5%. Specialty pharmaceuticals, including high-cost biotechnology products and orphan and ultra-orphan drugs, are used for chronic or rare conditions like cancer and AIDS. Oncology dominates the market with a 42% share in 2023. The market also focuses on Multiple Sclerosis, inflammatory conditions, and infectious diseases. Oral administration is the most common, but parenteral and transdermal methods are significant. Offline channels lead in distribution, and North America is the largest market. Teva Pharmaceutical Industries Ltd. holds about 40% of this concentrated market. Growth drivers include increasing chronic and rare disease prevalence and technological advancements in biotechnology and personalized medicine. High costs and stringent regulatory processes are the main challenges, but opportunities lie in increasing global awareness and educational initiatives.
To read more, click here.
[Source: GlobeNewswire, January 3rd, 2023]